NRG-HN003: Phase I and Expansion Cohort Study of Adjuvant Pembrolizumab, Cisplatin and Radiation Therapy in Pathologically High-Risk Head and Neck Cancer

SIMPLE SUMMARY: The anti-PD1 monoclonal antibody pembrolizumab improves survival in recurrent/metastatic head and neck squamous cell carcinoma. Patients with locoregional, pathologically high-risk disease recur frequently despite adjuvant cisplatin–radiation therapy. Targeting PD1 may reverse immuno...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Cancers (Basel)
Hlavní autoři: Bauman, Julie E., Harris, Jonathan, Uppaluri, Ravindra, Yao, Min, Ferris, Robert L., Chen, Josephine, Jordan, Richard C., Joshi, Nikhil P., Jujjuvaparu, Srinivas, Blakaj, Dukagjin M., Henson, Christina, Sheqwara, Jawad, Mell, Loren K., Sen, Neilayan, Clump, David A., Garg, Madhur K., Yilmaz, Emrullah, Torres-Saavedra, Pedro, Le, Quynh-Thu
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2021
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC8230356/
https://ncbi.nlm.nih.gov/pubmed/34207599
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13122882
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky